Literature DB >> 11085521

Sex hormone-induced carcinogenesis in Rb-deficient prostate tissue.

Y Wang1, S W Hayward, A A Donjacour, P Young, T Jacks, J Sage, R Dahiya, R D Cardiff, M L Day, G R Cunha.   

Abstract

The retinoblastoma (Rb) gene product is a prototypic tumor suppressor. Mice lacking the Rb gene are not viable and die in utero at approximately 13 days of gestation. In this study, we have rescued Rb-/- prostates by grafting pelvic organ rudiments from Rb-/- mouse embryos under the renal capsule of adult male nude mouse hosts. Grafts of embryonic pelvic organs developed into functional prostatic tissue. Some of the prostatic tissue generated was further used to construct chimeric prostatic tissue recombinants by combining wild-type rat urogenital mesenchyme (rUGM) with Rb-/- and Rb+/+ prostatic epithelium (PRE). The tissue recombinants were grown as subcapsular renal grafts and treated from the time of grafting with Silastic capsules containing 25 mg of testosterone plus 2.5 mg of estradiol. During 5-8 weeks of hormone treatment, rUGM+Rb+/+PRE tissue recombinants developed prostatic hyperplasia, whereas PRE in rUGM+Rb-/-PRE tissue recombinants developed hyperplasia, atypical hyperplasia, and carcinoma. During carcinogenesis in rUGM+Rb-/-PRE tissue recombinants, prostatic epithelial cells of the basal lineage disappeared, whereas the luminal cells underwent carcinogenesis. Epithelial E-cadherin almost totally disappeared. In all cases, epithelial PCNA labeling was elevated in tissue recombinants containing Rb-/- versus Rb+/+ epithelium. These epithelial changes were associated with almost total loss of smooth muscle cells in the stroma. In contrast, in untreated hosts rUGM+Rb+/+PRE tissue recombinants developed normally, and rUGM+Rb-/-PRE tissue recombinants developed mild epithelial hyperplasia. The results of this study demonstrate that Rb-/- prostatic tissue can be rescued from embryonic lethal mice and used to test its susceptibility to hormonal carcinogenesis. Deletion of the Rb gene predisposes prostatic epithelium to hyperplasia and increases proliferative activity Susceptibility to hormonal carcinogenesis in response to exogenous testosterone + estradiol is manifested in the progression from atypica hyperplasia to carcinoma. Thus, these findings demonstrate that the absence of the Rb tumor suppressor gene may predispose prostatic epithelial cells to carcinogenesis. Rescue of organs from Rb-/- embryos not only provides an opportunity to analyze the Rb gene pathway in the development and progression of prostate cancer but also provides an opportunity for specifically evaluating the role of the Rb pathway in development and carcinogenesis in other organs, such as the mammary gland and colon. Because rUGM greatly stimulates prostatic epithelial proliferation, the tissue recombinant model is a particularly useful tool for assessing the functional role of other genes in prostatic carcinogenesis through use of the appropriate transgenic or gene knockout mice.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11085521

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  33 in total

1.  E2f binding-deficient Rb1 protein suppresses prostate tumor progression in vivo.

Authors:  Huifang Sun; Yanqing Wang; Meenalakshmi Chinnam; Xiaojing Zhang; Simon W Hayward; Barbara A Foster; Alexander Y Nikitin; Marcia Wills; David W Goodrich
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-27       Impact factor: 11.205

2.  pRb-Independent growth arrest and transcriptional regulation of E2F target genes.

Authors:  Michael T McCabe; Odinaka J Azih; Mark L Day
Journal:  Neoplasia       Date:  2005-02       Impact factor: 5.715

3.  Androgen hormone action in prostatic carcinogenesis: stromal androgen receptors mediate prostate cancer progression, malignant transformation and metastasis.

Authors:  Emily A Ricke; Karin Williams; Yi-Fen Lee; Suzana Couto; Yuzhuo Wang; Simon W Hayward; Gerald R Cunha; William A Ricke
Journal:  Carcinogenesis       Date:  2012-04-25       Impact factor: 4.944

Review 4.  Time to stratify? The retinoblastoma protein in castrate-resistant prostate cancer.

Authors:  Ana Aparicio; Robert B Den; Karen E Knudsen
Journal:  Nat Rev Urol       Date:  2011-08-02       Impact factor: 14.432

5.  High circulating estrogens and selective expression of ERβ in prostate tumors of Americans: implications for racial disparity of prostate cancer.

Authors:  Zakaria Y Abd Elmageed; Krzysztof Moroz; Sudesh K Srivastav; Zhide Fang; Byron E Crawford; Krishnarao Moparty; Raju Thomas; Asim B Abdel-Mageed
Journal:  Carcinogenesis       Date:  2013-05-08       Impact factor: 4.944

6.  Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma.

Authors:  Hsueh-Li Tan; Akshay Sood; Hameed A Rahimi; Wenle Wang; Nilesh Gupta; Jessica Hicks; Stacy Mosier; Christopher D Gocke; Jonathan I Epstein; George J Netto; Wennuan Liu; William B Isaacs; Angelo M De Marzo; Tamara L Lotan
Journal:  Clin Cancer Res       Date:  2013-12-09       Impact factor: 12.531

7.  Prostatic intraepithelial neoplasia in genetically engineered mice.

Authors:  Jae-Hak Park; Judy E Walls; Jose J Galvez; Minjung Kim; Cory Abate-Shen; Michael M Shen; Robert D Cardiff
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

Review 8.  Current mouse and cell models in prostate cancer research.

Authors:  Xinyu Wu; Shiaoching Gong; Pradip Roy-Burman; Peng Lee; Zoran Culig
Journal:  Endocr Relat Cancer       Date:  2013-06-24       Impact factor: 5.678

9.  Activation of beta-Catenin in mouse prostate causes HGPIN and continuous prostate growth after castration.

Authors:  Xiuping Yu; Yongqing Wang; Ming Jiang; Brian Bierie; Pradip Roy-Burman; Michael M Shen; Makoto Mark Taketo; Marcia Wills; Robert J Matusik
Journal:  Prostate       Date:  2009-02-15       Impact factor: 4.104

10.  Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer.

Authors:  Teresa Chiaverotti; Suzana S Couto; Annemarie Donjacour; Jian-Hua Mao; Hiroki Nagase; Robert D Cardiff; Gerald R Cunha; Allan Balmain
Journal:  Am J Pathol       Date:  2007-12-21       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.